Regencell Bioscience Holdings (RGC) Cash & Equivalents (2020 - 2024)

Regencell Bioscience Holdings has reported Cash & Equivalents for 5 years, with the latest figure at $3.0 million in Q2 2024.

• For the quarter ending Q2 2024, Cash & Equivalents rose 89.24% year-over-year to $3.0 million; the trailing twelve-month figure through Jun 2024 stood at $3.0 million (up 89.24% YoY), and the FY2024 full-year result was $3.0 million, up 89.24% from the prior year.
• Cash & Equivalents for Q2 2024 stood at $3.0 million, up from $1.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $6.4 million in Q2 2022, with the low at $59413.0 in Q2 2021.
• Historically, Cash & Equivalents has averaged $2.3 million across 5 years, with a median of $1.6 million in 2023.
• Annual changes were most pronounced in 2021 — Cash & Equivalents slumped 84.65% — and 2022, when it surged 10700.66%.
• Regencell Bioscience Holdings' Cash & Equivalents stood at $386979.0 in 2020, then tumbled by 84.65% to $59413.0 in 2021, then surged by 10700.66% to $6.4 million in 2022, then sank by 75.61% to $1.6 million in 2023, then jumped by 89.24% to $3.0 million in 2024.
• The last three Cash & Equivalents figures came in at $3.0 million (Q2 2024), $1.6 million (Q2 2023), and $6.4 million (Q2 2022), per Business Quant data.